Movement Alert｜Twist Bioscience Corp Overnight Rise 5.18%, earnings expectations and Lilly TuneLab collaboration remain in focus

Market Focus11-11 16:04

On November 11, Twist Bioscience Corp rose 5.18% Overnight, trading at $138.98 per share, with turnover of $279,700.

The move coincided with continued market focus on the company’s November 12 earnings report, consensus expectations for about $123 million in quarterly revenue, and progress in its antibody characterization data services collaboration with Eli Lilly’s TuneLab platform.

Available market commentary points to expected quarterly revenue growth of about 25.96% year over year and adjusted EPS projected at a loss of $0.37 to $0.44 per share, with narrowing losses remaining a key watchpoint. Separately, Twist Bioscience Corp previously announced an agreement to support Lilly TuneLab with antibody characterization data services, while broader discussion has also highlighted AI drug discovery-related order expectations and constructive institutional sentiment, including an average target price near $150.33.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment